Dupixent Asthma Drug Shows Promise in Treating COPD, Boosting Sanofi and Regeneron Shares

Sanofi and Regeneron's jointly developed asthma drug Dupixent has shown promise in treating COPD patients, according to new data from a phase three clinical trial. The drug reduced bad bouts of chronic obstructive pulmonary disease by 30% compared with a placebo over 52 weeks. Dupixent is already approved for asthma and some skin conditions, but it could become the first new treatment in over a decade for COPD. The trial enrolled COPD patients with type 2 inflammation, and those who received Dupixent showed improvements in lung function, quality of life, and respiratory symptoms. A second phase three trial of Dupixent in COPD is ongoing, with data expected in 2024.